Genmab — November 2023

Bulder

In Majestec 1 tec+dara had 63% ORR and 39% CR in 4. Line. The ph 3 study is 2.-4. Line.

Bulder

Majestec 3 will probably read out in 2025.

Bulder

Just a moment...

(www.nejm.org)

E_L

Majestec1 was mono I believe, Majestec2 with Dara i think , has data already, need to look it up

Bulder

Yes you are right. Majestec 1 was mono. In Majestec 2: the overall response rate (ORR) was 93.5 percent.1 Among all patients in the trial, VGPRs or better were achieved by 90.3 percent of patients, and 54.8 percent of patients achieved a complete response (CR) or better.

Bulder

Site Maintenance

(www.jnj.com)

Bulder

Majestec 2 also combined with lenalidimide. So DR+Tec.

Bulder

Will be hard to beat for bela maf.

Bulder

I wonder why GSK didn’t combine bela maf with len.

E_L

i think they also have a Ph 1/2 with len. They have more trials , they "Dreamm"
a lot

E_L

Tisotumab Vedotin Survival Data in Cervical Cancer Are “Game-Changing" https://www.cancernetwork.com/view/tisotumab-vedotin-survival-data-in-cervical-cancer-are-game-changing-

E_L

Trial investigator Brian Slomovitz, MD, Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center, discusses results from the global, randomized, open-label Phase 3 innovaTV 301 trial
https://www.youtube.com/watch?v=HIZzLVIh15c

Don_Joning

Det lyder umiddelbart rigtig godt med Tiso, det er en frygtelig sygdom!

Solsen

AbbVie will pay $31.26 per share in cash, or approximately $10.1 billion, to acquire ImmunoGen, gaining the antibody-drug conjugate Elahere (mirvetuximab soravtansine).